SIC
PCRX icon

SJS Investment Consulting’s Pacira BioSciences PCRX Stock Holding History

SJS Investment Consulting’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5
Closed -$144 – 1700
2024
Q2 		$144 Hold
5
– – ﹤0.01% 1554
2024
Q1 		$147 Hold
5
– – ﹤0.01% 1531
2023
Q4 		$169 Buy
5
+1
+25% +$29 ﹤0.01% 1491
2023
Q3 		$123 Sell
4
-1
-20% -$36 ﹤0.01% 1519
2023
Q2 		$201 Sell
5
-1
-17% -$41 ﹤0.01% 1406
2023
Q1 		$245 Buy
6
+1
+20% +$40 ﹤0.01% 1319
2022
Q4 		$193 Buy
5
+1
+25% +$49 ﹤0.01% 1419
2022
Q3 		$0 Buy
+4
New +$222 ﹤0.01% 1416
2022
Q1 		$12K Buy
163
+1
+0.6% +$67 ﹤0.01% 371
2021
Q4 		$10K Buy
+162
New +$8.93K ﹤0.01% 375

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

SJS Investment Consulting's PCRX Position: Q3 2024 in Review

SJS Investment Consulting sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 5 shares — an estimated $144 sold.

SJS Investment Consulting first reported a position in PCRX in Q4 2021 and held it in 10 quarters. The position peaked at $12K in Q1 2022. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

  • SJS Investment Consulting reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
  • SJS Investment Consulting sold 5 Pacira BioSciences shares in Q3 2024, an estimated $144.
  • SJS Investment Consulting first reported a position in Pacira BioSciences in Q4 2021 and held it in 10 quarters.
  • SJS Investment Consulting's Pacira BioSciences position peaked at $12K in Q1 2022.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on SJS Investment Consulting's 13F filing for Q3 2024, filed 16 Oct 2024.